Atty Docket No.: R0147B-REG USSN: 10/663,314

Claim Listing

1. (Previously Presented) A compound of the formula:

$$(R^4)$$
 $\stackrel{[i]}{\underset{R^2}{\longrightarrow}} S(O)$ $\stackrel{R^1}{\underset{R^3}{\longrightarrow}}$

or a pharmaceutically acceptable salt thereof, wherein

n is 0, 1 or 2;

p is 1 or 2;

R1 is aryl;

R² is a heterocyclyl;

R³ is hydrogen, alkyl, or -C(=O)-R⁵, where R⁵ is alkyl, alkoxy, aryl, or aryloxy; and

each R⁴ is independently hydrogen, hydroxy, cyano, alkyl, alkoxy, thioalkyl, alkylthio, halo, haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, alkylcarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, amino, alkylamino, dialkylamino, alkylamino, alkylamino, alkylcarbonylamino, alkylcarbonyl(alkylamino), alkylaminosulfonyl, alkylsulfonylamino or methylenedioxyhydrogen, alkyl, alkoxy, halo, or haloalkyl.

- 2. (Original) The compound according to Claim 1, wherein p is 1 and R⁴ is located at the 6-position of the indolering system.
- 3. (Original) The compound according to Claim 1, wherein R² is optionally substituted piperazin-1-yl or optionally substituted piperidin-4-yl.

Atty Docket No.: R0147B-REG USSN: 10/663,314

- 4. (Original) The compound according to Claim 3, wherein R² is piperazin-1-yl, 4-methylpiperazin-1-yl, 3,5-dimethylpiperazin-1-yl, N-methyl piperidin-4-yl or piperidin-4-yl.
- 5. (Original) The compound according to Claim 4, wherein R² is 4-methylpiperazin-1-yl.
- 6. (Previously Presented) The compound according to Claim 3, wherein R¹ is optionally substituted phenyl.
- 7. (Previously Presented) The compound according to Claim 6, wherein R¹ is phenyl which is optionally substituted with alkyl, halo or haloalkyl.
- 8. (Previously Presented) The compound according to Claim 7, wherein R¹ is phenyl, 2,3-dichlorophenyl, 2-fluorophenyl, 2-methylphenyl, 2-trifluoromethylphenyl, or 3-bromophenyl.
 - 9. (Original) The compound according to Claim 6, wherein n is 2.
- 10. (Original) The compound according to Claim 9, wherein \mathbb{R}^3 is hydrogen, methyl, or $-\mathbb{C}(=0)-\mathbb{R}^5$, where \mathbb{R}^5 is alkoxy.
- 11. (Previously Presented) The compound according to Claim 1, wherein R¹ is phenyl which is optionally substituted with a substituent selected from the group consisting of alkyl, halo and haloalkyl.
- 12. (Previously Presented) The compound according to Claim 11, wherein R¹ is phenyl, 2,3-dichlorophenyl, 2-fluorophenyl, 2-methylphenyl, 2-trifluoromethylphenyl, or 3-bromophenyl.
 - 13. (Original) The compound according to Claim 11, wherein n is 2.
- 14. (Original) The compound according to Claim 13, wherein R² is optionally substituted piperazin-1-yl or optionally substituted piperidin-4-yl.

HALLR6 #139574 v) Page 3 of 7 R0147B-REG

Atty Docket No.: R0147B-REG USSN: 10/663,314

15. (Original) The compound according to Claim 14, wherein R2 is piperazin-1-yl, 4-methylpiperazin-1-yl, 3,5-dimethylpiperazin-1-yl, N-methyl piperidin-4-yl or piperidin-4-yl.

650 855 5322

- 16. (Original) The compound according to Claim 15, wherein R³ is hydrogen, methyl or $-C(=0)-R^5$, where R^5 is alkoxy.
 - 17. (Original) The compound according to Claim 1, wherein n is 2.
- 18. (Previously Presented) The compound according to Claim 17, wherein R1 is phenyl which is optionally substituted with a substituent selected from the group consisting of alkyl, halo, haloalkyl, and a mixture thereof.
- 19. (Original) The compound according to Claim 18, wherein R² is optionally substituted piperazin-1-yl or optionally substituted piperidin-4-yl.
- 20. (Original) The compound according to Claim 19, wherein R3 is hydrogen, methyl or -C(=O)-R⁵, where R⁵ is alkoxy.
- 21. (Original) The compound according to Claim 1, wherein said compound is 2-benzenesulfonyl-7-(4-methylpiperazin-1-yl)-1H-indole.
- 22. (Currently Amended) A method for producing a compound of claim 1, said method comprising contacting a substituted indole of the formula:

$$(R^4)_{\overline{p}}$$
 $\stackrel{\parallel}{\underset{\mathbb{R}^2}{\bigvee}}$ $\stackrel{N}{\underset{\mathbb{R}^{3'}}{\bigvee}}$

wherein R3 is alkyl or -C(=O)-R5, and p, R2, R4 and R5 are as recited in claim 1

- (i) with a base to produce a deprotonated indole; and
- (ii) contacting the deprotonated indole with a sulfonylating agent of the formula:

$$Y-SO_2-R^1$$

where Y is halide and R1 is as recited in claim 1, or a disulfide agent of the formula:

HALLR6 #139574 v1

Page 4 of 7

R0147B-REG

Atly Docket No.: R0147B-REG USSN: 10/663,314

to produce a 2-substituted indole of the formula:

$$(R^4)_{p}$$
 $\downarrow I$
 $\downarrow I$

- (iii) optionally oxidizing the sulfur with an oxidizing agent; and
- optionally removing the protecting group \mathbb{R}^{3} to produce the compound (iv) of claim 1 wherein R3 is hydrogen.
 - 23. (Original) The method of Claim 22, wherein Y is fluorine.
 - 24. (Original) A composition comprising:
 - (a) a therapeutically effective amount of a compound of Claim 1; and
 - **(b)** a pharmaceutically acceptable carrier.
- 25. (Currently Amended) A method for treating a 5-HT6-mediated memory disorder or Alzheimer's disease CNS disease state in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound of Claim 1.
 - 26. (Canceled)
 - 27. (Canceled)
 - 28. (Canceled)